Alterity Therapeutics (ATHE) spotlights upcoming Canaccord presentation as it prepares for a Phase 3 MSA trial
Market Chameleon (Mon, 12-Oct 11:57 AM)
ATHE spotlights a 52% slowing in MSA functional decline after CSF NfL-adjusted Phase 2 analysis
Market Chameleon (Mon, 5-Oct 11:57 AM)
